omniture

Mason Group Realized Significant Breakthrough in 2017 Interim Results

Mason Group Holdings Limited
2017-08-29 23:42 4965

Multiple Acquisitions and Investments Drive Revenue Growth

Continued Search for Acquisition Opportunities for Global Expansion

HONG KONG, Aug. 29, 2017 /PRNewswire/ -- Mason Group Holdings Limited ("Mason" or "Group", SEHK Stock Code: 0273) announced its unaudited interim results for the six months ended 30 June 2017.

During the period, Mason took solid steps in its transformation of becoming a one-stop "Health and Wealth Solution Partner". Through the implementation of the unique "Enterprise + Finance" strategy, Mason has achieved satisfactory results in the first half of 2017. The Group's revenue increased by HKD1,260 million, loss attributable to the shareholders of the company narrowed down greatly to HKD25 million. The continuous improvement in business performance was the direct result of multiple acquisitions and investments which drove revenue growth, and the significant decrease of the net fair value loss on financial assets held for trading.

Mr. Joel Cheng, Mason's Chief Operation Officer, commented: "We are deeply encouraged by the great improvement in the Group's performance within a short period of time. During the period, not only have we expanded our existing brokerage services, securities margin financing services, leveraged and acquisitions financing, and mortgage and loan business; but also our financial platform into an all-round service platform with a powerful global network that can provide wealth and asset management products to our customers. The Group is on its path to become a worldwide Healthcare Finance group with the ability to allocate assets internationally. On the enterprise front, through multiple acquisitions and investments, Mason has successfully developed a vast mother-infant-child ecosystem in China. The Group will continue to look for mother-infant-child opportunities in the China market and other emerging Asian markets. Leveraging on the growth of our enterprise segment, we hope it can give our financial services a boost."

During the Period, the Company completed multiple acquisitions and investment projects in the mother-infant-child sector, including the acquisition of a 42.9% equity interest in Diagcor Technology, which is engaged in the genetic testing related business, for a total consideration of HKD214 million. In July, the Company – in tandem with the ASX-listed nutritional and health products company, Wattle Health Australia Limited – acquired an 80% stake in Blend and Pack for a total consideration of HKD480 Million. These transactions marked Mason's further expansion along the value chain of the premium medical and mother-infant-child market. Mason's expansion is geared towards building an all-round mother-infant-child ecosystem, and an overall business position which allows it to capitalize on the development potential of the Greater China market, and ultimately to expand on a global scale.

Looking ahead, with the commencement of northbound bond trading in July 2017, and the imminent roll out of southbound bond trading, Channels such as the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect have long been major overseas platforms for mainland people to allocate their wealth. Hong Kong's position in connecting Mainland China and the world is becoming increasingly important. Embracing the thriving opportunities in Hong Kong's financial market, Mason will continue to develop its existing securities brokerages and margin financing businesses, while seeking commercial opportunities in the financial segments such as insurance and fund management. In addition, the Group will continue to assess potential acquisition targets that are beneficial to the development of the Group and those which will create synergies with its other business sectors. Also, the Company aims to acquire financial institutions in the US, Europe, and Asia, in order to build a financial platform with world-wide asset allocation capabilities.

As to the development of its enterprise segment, China's healthcare and medical sector is expected to grow rapidly with its aging population, the two-child policy, coupled with the rising health awareness and increase in the domestic per capita disposable income. The Company will continue to engage in healthcare and mother-infant-child related businesses and endeavor to deliver high quality products and services. Mason also intends to build up industry-specific private equity and fixed interest funds, thereby creating a synergistic mechanism where the financial, healthcare and medical sector can complement and benefit each other.

Mr. Alex Ko, Joint Chairman and CEO of Mason Group concluded: "All projects we have acquired and invested in the first half of the year have performed admirably, generating stable and healthy revenue for the Company. This proves that our 'Enterprise + Finance' strategy and focus on healthcare and medical industry are correct. The newly acquired companies are expected to become key drivers of revenue. Looking ahead, the Company will continue to pursue mergers and acquisitions in both the enterprise and financial segments, reinforcing a balanced and complementary development in both. Thanks to the Company's experienced management team, sound development strategies, and strong networks of clients and partners, I believe the Company will see rapid growth and bring satisfactory return to shareholders and investors."

~ End ~

About Mason Group

Mason Group Holdings Limited (stock code: 0273.HK) is a health and wealth solutions service conglomerate. It principally provides comprehensive financial services in Hong Kong, including dealing in securities, commodities broking, bullion trading services, provision of securities margin financing, provision of investment and corporate finance advisory services, investment in securities trading, money lending and investment holding. The Company is also principally engaged in the health care and mother-infant-child care related business. Capitalising on its existing big healthcare financial services platform, the Company continues to develop its business into direct investment, provision of wealth management complimenting the securities and fund management business. 

For inquiries, please contact Hill+Knowlton Strategies:

Daphne Chan

Sophie Liu

Tel: (852) 2894 6217

Tel: (852) 2894 6318

Email: mason.hkg@hkstrategies.com


Source: Mason Group Holdings Limited
Related Stocks:
HongKong:0273
collection